Genetic testing for lung cancer: reflex versus clinical selection

Editorial

Paul A Bunn Jr et al. J Clin Oncol. 2011.

. 2011 May 20;29(15):1943-5.

doi: 10.1200/JCO.2010.34.1974. Epub 2011 Apr 11.

No abstract available

Comment on

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. Paik PK, et al. J Clin Oncol. 2011 May 20;29(15):2046-51. doi: 10.1200/JCO.2010.33.1280. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483012 Free PMC article.

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or caboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. - PubMed
1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388. - PubMed
1. Lee JS, Park K, Kim S, et al. A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol. 2009;4(9):S283–S284.
1. Zhou C, et al. Program and abstracts of the 35th European Society of Medical Oncology Congress. Milan, Italy: 2010. Oct, Efficacy results from the randomized phase 3 OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Abstr. LBA13.
1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–1703. - PMC - PubMed